Cardone, K. E., Bacchus, S., Assimon, M. M., Pai, A. B. & Manley, H. J. Medication-related problems in CKD. Adv. Chronic Kidney Dis. 17, 404–412 (2010).
Konstantinidis, I. et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern. Med. 176, 121–124, (2016).
Roberts, D. M., Sevastos, J., Carland, J. E., Stocker, S. L. & Lea-Henry, T. N. Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens. Clin. J. Am. Soc. Nephrol. 13, 1254–1263 (2018).
Janse, R. J. et al. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician’s prescriptions to patient’s dispensations, medication adherence and persistence. Eur. J. Heart Fail. 24, 2185–2195 (2022).
Bramlage, P. et al. Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis. BMC Nephrol. 22, 184 (2021).
Rawson, T. M. et al. Optimizing antimicrobial use: challenges, advances and opportunities. Nat. Rev. Microbiol. 19, 747–758 (2021).
Alberta Health Services Pharmacy. Drug Stewardship: Information for Health Professionals https://www.albertahealthservices.ca/phm/Page17557.aspx#:~:text=Drug%20Stewardship%20within%20Alberta%20Health,by%20all%20staff%20and%20physicians (2023).
KDIGO Workgroup. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. https://doi.org/10.1016/j.kint.2023.10.018 (2024).
Long, C. L., Raebel, M. A., Price, D. W. & Magid, D. J. Compliance with dosing guidelines in patients with chronic kidney disease. Ann. Pharmacother. 38, 853–858 (2004).
Vondracek, S. F., Teitelbaum, I. & Kiser, T. H. Principles of kidney pharmacotherapy for the nephrologist: core curriculum 2021. Am. J. Kidney Dis. 78, 442–458 (2021).
Hepler, C. D. & Strand, L. M. Opportunities and responsibilities in pharmaceutical care. Am. J. Hosp. Pharm. 47, 533–543 (1990).
Manley, H. J. et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am. J. Kidney Dis. 41, 386–393 (2003).
Smyth, B. et al. Representativeness of randomized clinical trial cohorts in end-stage kidney disease: a meta-analysis. JAMA Intern. Med. 179, 1316–1324, (2019).
Budnitz, D. S. et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296, 1858–1866, (2006).
Levey, A. S. et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am. J. Kidney Dis. 75, 84–104 (2020).
Ricci, Z., Cruz, D. & Ronco, C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 73, 538–546 (2008).
Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron. Clin. Pract. 120, c179–184, (2012).
Mehta, R. L. et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. 66, 1613–1621 (2004).
Hoste, E. A. et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive care Med. 41, 1411–1423 (2015).
Chawla, L. S. & Kimmel, P. L. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int. 82, 516–524 (2012).
Jha, A. K. et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J. Am. Med. Inf. Assoc. 5, 305–314 (1998).
Adimadhyam, S. et al. Leveraging the capabilities of the FDA’s sentinel system to improve kidney care. J. Am. Soc. Nephrol. 31, 2506–2516 (2020).
Dave, C. V., Schneeweiss, S. & Patorno, E. Association of sodium-glucose cotransporter 2 inhibitor treatment with risk of hospitalization for Fournier gangrene among men. JAMA Intern. Med. 179, 1587–1590, (2019).
Douros, A. et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis : a multicenter cohort study. Ann. Intern. Med. 173, 417–425 (2020).
Fu, E. L. Target trial emulation to improve causal inference from observational data: what, why, and how? J. Am. Soc. Nephrol. 34, 1305–1314 (2023).
Bhandari, S. et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N. Engl. J. Med. 387, 2021–2032 (2022).
Fu, E. L. et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study. J. Am. Soc. Nephrol. 32, 424–435 (2021).
Guirguis-Blake, J. et al. Prescription of high-risk medications among patients with chronic kidney disease: a cross-sectional study from the Washington, Wyoming, Alaska, Montana and Idaho region Practice and Research Network. Fam. Pract. 35, 589–594 (2018).
Inker, L. A. & Titan, S. Measurement and estimation of GFR for use in clinical practice: core curriculum 2021. Am. J. Kidney Dis. 78, 736–749 (2021).
Sherman, D. S., Fish, D. N. & Teitelbaum, I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am. J. Kidney Dis. 41, 269–278 (2003).
Liu, X. et al. Non-GFR determinants of low-molecular-weight serum protein filtration markers in CKD. Am. J. Kidney Dis. 68, 892–900 (2016).
Shlipak, M. G., Inker, L. A. & Coresh, J. Serum cystatin C for estimation of GFR. JAMA 328, 883–884 (2022).
Stevens, L. A. et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 75, 652–660 (2009).
Foster, M. C. et al. Non-GFR determinants of low-molecular-weight serum protein filtration markers in the elderly: AGES-kidney and MESA-kidney. Am. J. Kidney Dis. 70, 406–414 (2017).
Knight, E. L. et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 65, 1416–1421 (2004).
Chang, A. R., Zafar, W. & Grams, M. E. Kidney function in obesity-challenges in indexing and estimation. Adv. Chronic Kidney Dis. 25, 31–40 (2018).
Sjostrom, P., Tidman, M. & Jones, I. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand. J. Clin. Lab. Invest. 65, 111–124 (2005).
Schei, J. et al. Residual associations of inflammatory markers with eGFR after accounting for measured GFR in a community-based cohort without CKD. Clin. J. Am. Soc. Nephrol. 11, 280–286 (2016).
Melsom, T. et al. Estimated GFR is biased by non-traditional cardiovascular risk factors. Am. J. Nephrol. 41, 7–15 (2015).
Xin, C., Xie, J., Fan, H., Sun, X. & Shi, B. Association between serum cystatin C and thyroid diseases: a systematic review and meta-analysis. Front. Endocrinol. 12, 766516 (2021).
Inker, L. A. & Titan, S. Measurement and estimation of GFR for use in clinical practice: core curriculum 2021. Am. J. Kidney Dis. S0272-6386, 00707–00701 (2021).
Levey, A. S., Inker, L. A. & Coresh, J. GFR estimation: from physiology to public health. Am. J. Kidney Dis. 63, 820–834 (2014).
Levey, A. S., Coresh, J., Tighiouart, H., Greene, T. & Inker, L. A. Measured and estimated glomerular filtration rate: current status and future directions. Nat. Rev. Nephrol. 16, 51–64 (2020).
Vidal, L., Shavit, M., Fraser, A., Paul, M. & Leibovici, L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 331, 263 (2005).
US Food and Drug Administration. Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing and Labeling. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-renal-function-study-design-data-analysis-and-impact-dosing (2020).
Cockcroft, D. W. & Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31–41 (1976).
Delanaye, P. et al. Performance of creatinine-based equations to estimate glomerular filtration rate with a methodology adapted to the context of drug dosage adjustment. Br. J. Clin. Pharmacol. 88, 2118–2127 (2022).
Kwon, S. et al. The long-term effects of metformin on patients with type 2 diabetic kidney disease. Diabetes Care 43, 948–955 (2020).
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854–865 (1998).
Salpeter, S. R., Greyber, E., Pasternak, G. A. & Salpeter, E. E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2010, Cd002967 (2010).
Lazarus, B. et al. Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study. JAMA Intern. Med. 178, 903–910 (2018).
Levey, A. S. et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145, 247–254 (2006).
Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009).
Inker, L. A. et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N. Engl. J. Med. 385, 1737–1749 (2021).
Peters, B. J. et al. Impact of serum cystatin C-based glomerular filtration rate estimates on drug dose selection in hospitalized patients. Pharmacotherapy 38, 1068–1073 (2018).
Carrero, J. J. et al. Discordances between creatinine- and cystatin C-based estimated GFR and adverse clinical outcomes in routine clinical practice. Am. J. Kidney Dis. 82, 534–542 (2023).
Markos, J. R. et al. Clinician perspectives on inpatient cystatin C utilization: a qualitative case study at Mayo Clinic. PLoS One 15, e0243618 (2020).
Fu, E. L. et al. Accuracy of GFR estimating equations in patients with discordances between creatinine and cystatin C-based estimations. J. Am. Soc. Nephrol. 34, 1241–1251 (2023).
Frazee, E. et al. Cystatin C-guided vancomycin dosing in critically Ill patients: a quality improvement project. Am. J. Kidney Dis. 69, 658–666 (2017).
Titan, S. et al. Performance of indexed and nonindexed estimated GFR. Am. J. Kidney Dis. 76, 446–449 (2020).
Swartling, O. et al. Sex differences in the recognition, monitoring, and management of CKD in health care: an observational cohort study. J. Am. Soc. Nephrol. 33, 1903–1914 (2022).
Bosi, A. et al. Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care. Clin. Kidney J. 15, 442–451 (2022).
Collister, D., Saad, N., Christie, E. & Ahmed, S. Providing care for transgender persons with kidney disease: a narrative review. Can. J. Kidney Health Dis. 8, 2054358120985379 (2021).
Bots, S. H. et al. Adverse drug reactions to guideline-recommended heart failure drugs in women: a systematic review of the literature. JACC Heart Fail. 7, 258–266 (2019).
Zucker, I. & Prendergast, B. J. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol. Sex. Differ. 11, 32 (2020).
Mauvais-Jarvis, F. et al. Sex- and gender-based pharmacological response to drugs. Pharmacol. Rev. 73, 730–762 (2021).
Soldin, O. P. & Mattison, D. R. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 48, 143–157 (2009).
Bots, S. H. et al. Heart failure medication dosage and survival in women and men seen at outpatient clinics. Heart 107, 1748–1755 (2021).
Santema, B. T. et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet 394, 1254–1263 (2019).
Driessen, J., Vree, T. & Guelen, P. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesthesiol. Belg. 42, 149–155 (1991).
Urakami, T. et al. Is trimethoprim/sulfamethoxazole-associated increase in serum creatinine a pseudo-elevation or true nephrotoxicity? J. Infect. Chemother. 27, 1193–1197 (2021).
Miano, T. A. et al. Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Med. 48, 1144–1155 (2022).
Teaford, H. R. et al. Patterns of cystatin C uptake and use across and within hospitals. Mayo Clin. Proc. 95, 1649–1659 (2020).
Brown, C. S., Kashani, K. B., Clain, J. M. & Frazee, E. N. Cystatin C falsely underestimated GFR in a critically ill patient with a new diagnosis of AIDS. Case Rep. Nephrol. 2016, 9349280 (2016).
Sangla, F. et al. Measured and estimated glomerular filtration rate in the ICU: a prospective study. Crit. Care Med. 48, e1232–e1241 (2020).
Claudel, S. E., Gandhi, M., Patel, A. B. & Verma, A. Estimating kidney function in patients with cancer: a narrative review. Acta Physiol. 238, e13977 (2023).
Casal, M. A., Nolin, T. D. & Beumer, J. H. Estimation of kidney function in oncology: implications for anticancer drug selection and dosing. Clin. J. Am. Soc. Nephrol. 14, 587–595 (2019).
Porta, C. et al. KDIGO controversies conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int. 98, 1108–1119 (2020).
Sandhu, G. et al. International consensus guideline for anticancer drug dosing in kidney dysfunction (ADDIKD): a standardized approach to assessing kidney function in cancer patients and its application to anticancer drug dosing. J. Clin. Oncol. 40, e13518–e13518 (2022).
Barreto, J. N. et al. Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function. Clin. Transl. Sci. 15, 105–117 (2022).
Costa, E. S. V. T. et al. A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors. Kidney Int. 101, 607–614 (2022).
Kutzke, J. L. et al. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. Blood Adv. 6, 3844–3849 (2022).
Wiles, K. et al. Clinical practice guideline on pregnancy and renal disease. BMC Nephrol. 20, 401 (2019).
Coca, S. G., Singanamala, S. & Parikh, C. R. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 81, 442–448 (2012).
Perazella, M. A. Pharmacology behind common drug nephrotoxicities. Clin. J. Am. Soc. Nephrol. 13, 1897–1908 (2018).
Blair, M. et al. Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review. Am. J. Nephrol. 52, 85–97 (2021).
Kim, J. Y., Yee, J., Yoon, H. Y., Han, J. M. & Gwak, H. S. Risk factors for vancomycin-associated acute kidney injury: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 88, 3977–3989 (2022).
Perazella, M. A. & Rosner, M. H. Drug-induced acute kidney injury. Clin. J. Am. Soc. Nephrol. 17, 1220 (2022).
Wagner, L.-A., Tata, A. L. & Fink, J. C. Patient safety issues in CKD: core curriculum 2015. Am. J. Kidney Dis. 66, 159–169 (2015).
Davison, S. N. et al. Analgesic use in patients with advanced chronic kidney disease: a systematic review and meta-analysis. Can. J. Kidney Health Dis. 7, 2054358120910329 (2020).
Armstrong, M. J., Zhang, K., Ye, F., Klarenbach, S. W. & Pannu, N. I. Population-based analysis of nonsteroidal anti-inflammatory drug prescription in subjects with chronic kidney disease. Can. J. Kidney Health Dis. 10, 20543581221149621 (2023).
Nast, C. C. Medication-induced interstitial nephritis in the 21st century. Adv. Chronic Kidney Dis. 24, 72–79 (2017).
Klatte, D. C. F. et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology 153, 702–710 (2017).
Rossing, P. et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 102, S1–S127 (2022).
Clifford, K. M. et al. The risk and clinical implications of antibiotic-associated acute kidney injury: a review of the clinical data for agents with signals from the Food and Drug Administration’s Adverse Event Reporting System (FAERS) Database. Antibiotics 11, 1367 (2022).
Bosi, A. et al. Quality of laboratory biomarker monitoring during treatment with lithium in patients with bipolar disorder. Bipolar Disord. 25, 499–506 (2023).
Bosi, A. et al. Absolute and relative risks of kidney outcomes associated with lithium vs valproate use in Sweden. JAMA Netw. Open. 6, e2322056 (2023).
Szummer, K. et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J. Am. Heart Assoc. 6, e004925 (2017).
Laliberte, M. C. et al. Use of over-the-counter medications and natural products in patients with moderate and severe chronic renal insufficiency. Am. J. Kidney Dis. 49, 245–256 (2007).
Akyol, A. D., Yildirim, Y., Toker, E. & Yavuz, B. The use of complementary and alternative medicine among chronic renal failure patients. J. Clin. Nurs. 20, 1035–1043 (2011).
Gabardi, S., Munz, K. & Ulbricht, C. A review of dietary supplement-induced renal dysfunction. Clin. J. Am. Soc. Nephrol. 2, 757–765 (2007).
Sriperumbuduri, S. & Hiremath, S. The case for cautious consumption: NSAIDs in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 28, 163–170 (2019).
Arfè, A. et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 354, i4857 (2016).
Gooch, K. et al. NSAID use and progression of chronic kidney disease. Am. J. Med. 120, 280 e281–280 e287 (2007).
Nelson, D. A., Marks, E. S., Deuster, P. A., O’Connor, F. G. & Kurina, L. M. Association of nonsteroidal anti-inflammatory drug prescriptions with kidney disease among active young and middle-aged adults. JAMA Netw. Open. 2, e187896 (2019).
Perneger, T. V., Whelton, P. K. & Klag, M. J. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 331, 1675–1679 (1994).
Sandler, D. P., Burr, F. R. & Weinberg, C. R. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann. Intern. Med. 115, 165–172 (1991).
Novick, T. K. et al. Associations of opioid prescriptions with death and hospitalization across the spectrum of estimated GFR. Clin. J. Am. Soc. Nephrol. 14, 1581–1589 (2019).
Zhan, M. et al. Association of opioids and nonsteroidal anti-inflammatory drugs with outcomes in CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) study. Am. J. Kidney Dis. 76, 184–193 (2020).
Luyckx, V. A. Nephrotoxicity of alternative medicine practice. Adv. Chronic Kidney Dis. 19, 129–141 (2012).
Yang, B. et al. Nephrotoxicity and Chinese herbal medicine. Clin. J. Am. Soc. Nephrol. 13, 1605–1611 (2018).
Kilis-Pstrusinska, K. & Wiela-Hojenska, A. Nephrotoxicity of herbal products in Europe — a review of an underestimated problem. Int. J. Mol. Sci. 22, 4132 (2021).
Steenkamp, V. & Stewart, M. J. Nephrotoxicity associated with exposure to plant toxins, with particular reference to Africa. Ther. Drug. Monit. 27, 270–277 (2005).
Koshy, K. M., Griswold, E. & Schneeberger, E. E. Interstitial nephritis in a patient taking creatine. N. Engl. J. Med. 340, 814–815 (1999).
Thorsteinsdottir, B., Grande, J. P. & Garovic, V. D. Acute renal failure in a young weight lifter taking multiple food supplements, including creatine monohydrate. J. Ren. Nutr. 16, 341–345 (2006).
Xuan, B. H. et al. Ichthyotoxic ARF after fish gallbladder ingestion: a large case series from Vietnam. Am. J. Kidney Dis. 41, 220–224 (2003).
Hsu, P. P. Natural medicines comprehensive database. J. Med. Libr. Assoc. 90, 114 (2002).
Song, Y.-K. et al. Effectiveness of clinical pharmacist service on drug-related problems and patient outcomes for hospitalized patients with chronic kidney disease: a randomized controlled trial. J. Clin. Med. 10, 1788 (2021).
Tesfaye, W. H. et al. Effect of pharmacist‐led medication review on medication appropriateness in older adults with chronic kidney disease. J. Pharm. Pract. Res. 49, 471–476 (2019).
Patel, H. R., Pruchnicki, M. C. & Hall, L. E. Assessment for chronic kidney disease service in high-risk patients at community health clinics. Ann. Pharmacother. 39, 22–27 (2005).
SHPA Committee of Specialty Practice in Clinical Pharmacy Medication Reconciliation. Chapter 1: medication reconciliation. J. Pharm. Pract. Res. 43, S6–S12 (2013).
St Peter, W. L. Improving medication safety in chronic kidney disease patients on dialysis through medication reconciliation. Adv. Chronic Kidney Dis. 17, 413–419 (2010).
Mason, N. A. & Bakus, J. L. Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease. Semin. Dial. 23, 55–61 (2010).
St Peter, W. L., Wazny, L. D. & Patel, U. D. New models of CKD care including pharmacists: improving medication reconciliation and medication management. Curr. Opin. Nephrol. Hypertension 22, 656 (2013).
McCarthy, L. M., Visentin, J. D. & Rochon, P. A. Assessing the scope and appropriateness of prescribing cascades. J. Am. Geriatr. Soc. 67, 1023–1026 (2019).
Gurwitz, J. H. et al. Thiazide diuretics and the initiation of anti-gout therapy. J. Clin. Epidemiol. 50, 953–959 (1997).
Bradley, J. D., Brandt, K. D., Katz, B. P., Kalasinski, L. A. & Ryan, S. I. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N. Engl. J. Med. 325, 87–91 (1991).
McCarthy, L. M. et al. ThinkCascades: a tool for identifying clinically important prescribing cascades affecting older people. Drugs Aging 39, 829–840 (2022).
Agarwal, R. et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N. Engl. J. Med. 385, 2507–2519 (2021).
Wang, G. H., Morris, E. J., Smith, S. M., Hallas, J. & Vouri, S. M. Continued potassium supplementation use following loop diuretic discontinuation in older adults: an evaluation of a prescribing cascade relic. J. Am. Geriatr. Soc. 71, 505–515 (2023).
Rochon, P. A. & Gurwitz, J. H. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 315, 1096–1099 (1997).
Savage, R. D. et al. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern. Med. 180, 643–651 (2020).
Rochon, P. A. & Gurwitz, J. H. The prescribing cascade revisited. Lancet 389, 1778–1780 (2017).
Morris, E. J., Brown, J. D., Manini, T. M. & Vouri, S. M. Differences in health-related quality of life among adults with a potential dihydropyridine calcium channel blocker–loop diuretic prescribing cascade. Drugs Aging 38, 625–632 (2021).
Brath, H. et al. What is known about preventing, detecting, and reversing prescribing cascades: a scoping review. J. Am. Geriatrics Soc. 66, 2079–2085 (2018).
Thompson, W. & Farrell, B. Deprescribing: what is it and what does the evidence tell us? Can. J. Hosp. Pharm. 66, 201 (2013).
Ibrahim, K. et al. A systematic review of the evidence for deprescribing interventions among older people living with frailty. BMC Geriatr. 21, 258 (2021).
Hall, R. K. et al. Stakeholder perspectives on factors related to deprescribing potentially inappropriate medications in older adults receiving dialysis. Clin. J. Am. Soc. Nephrol. 18, 1310–1320 (2023).
Mangin, D. et al. Legacy drug-prescribing patterns in primary care. Ann. Fam. Med. 16, 515–520 (2018).
Hall, R. K. et al. Risk of potentially inappropriate medications in adults with CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am. J. Kidney Dis. 78, 837–845.e1 (2021).
Kimura, H., Yoshida, S., Takeuchi, M. & Kawakami, K. Impact of potentially inappropriate medications on kidney function in chronic kidney disease: retrospective cohort study. Nephron 147, 177–184 (2023).
O’Mahony, D. et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 44, 213–218 (2015).
By the American Geriatrics Society Beers Criteria Update Expert, P. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 71, 2052–2081 (2023).
Nawaz, S., Cleveland, T., Gaines, P. A. & Chan, P. Clinical risk associated with contrast angiography in metformin treated patients: a clinical review. Clin. Radiol. 53, 342–344 (1998).
Thiruvenkatarajan, V., Meyer, E. J., Nanjappa, N., Van Wijk, R. M. & Jesudason, D. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br. J. Anaesth. 123, 27–36 (2019).
Whiting, P. et al. What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis. BMJ Open. 7, e012674 (2017).
Rudnick, M. R. et al. The controversy of contrast-induced nephropathy with intravenous contrast: what is the risk? Am. J. Kidney Dis. 75, 105–113 (2020).
The Royal College of Radiologists. Joint Advisory Statement between The Royal College of Radiologists & Royal College Emergency Medicine Regarding Emergency Computed Tomography Scans and the Use of Intravenous Iodinated Contrast Agents https://www.rcr.ac.uk/news-policy/latest-updates/joint-advisory-statement-between-the-royal-college-of-radiologists-royal-college-emergency-medicine-regarding-emergency-computed-tomography-scans-and-the-use-of-intravenous-iodinated-contrast-agents/ (2023).
Hollmann, C., Fernandes, N. L. & Biccard, B. M. A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery. Anesth. Analg. 127, 678–687 (2018).
Coca, S. G. et al. Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrol. Dial. Transpl. 28, 2787–2799 (2013).
Bamgboye, A. O., Oni, I. O. & Collier, A. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Eur. J. Clin. Pharmacol. 77, 651–657 (2021).
Humphrey, T. J., James, G., Wittbrodt, E. T., Zarzuela, D. & Hiemstra, T. F. Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD). Clin. Kidney J. 14, 2203–2212 (2021).
Martinez, Y. V., Benett, I., Lewington, A. J. P., Wierzbicki, A. S. & Guideline, C. Chronic kidney disease: summary of updated NICE guidance. BMJ 374, n1992 (2021).
Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J. Am. Coll. Cardiol. 79, 1757–1780 (2022).
Trevisan, M. et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur. J. Heart Fail. 20, 1217–1226 (2018).
Bidulka, P. et al. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care. BMC Med. 18, 195 (2020).
Leon, S. J. et al. Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am. J. Kidney Dis. 80, 164–173 e161 (2022).
Trevisan, M. et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur. J. Heart Fail. 23, 1698–1707 (2021).
Xu, Y. et al. Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes. Am. Heart J. 243, 177–186 (2022).
Janse, R. J. et al. Stopping versus continuing renin–angiotensin–system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data. Clin. Kidney J. 15, 1109–1119 (2022).
Hassan, Y., Al-Ramahi, R. J., Aziz, N. A. & Ghazali, R. Adverse drug events in hospitalized patients with chronic kidney disease. Int. J. Clin. Pharmacol. Ther. 48, 571–576 (2010).
Novick, T. K. et al. Prevalence of opioid, gabapentinoid, and NSAID use in patients with CKD. Clin. J. Am. Soc. Nephrol. 13, 1886–1888 (2018).
Long, B., Lentz, S., Koyfman, A. & Gottlieb, M. Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am. J. Emerg. Med. 44, 157–160 (2021).
Tully, A. P., Hammond, D. A., Li, C., Jarrell, A. S. & Kruer, R. M. Evaluation of medication errors at the transition of care from an ICU to non-ICU location. Crit. Care Med. 47, 543–549 (2019).
Gray, M. P. et al. Consensus obtained for the nephrotoxic potential of 167 drugs in adult critically Ill patients using a modified Delphi method. Drug. Saf. 45, 389–398 (2022).
Jones, D. C. & Hayslett, J. P. Outcome of pregnancy in women with moderate or severe renal insufficiency. N. Engl. J. Med. 335, 226–232 (1996).
Cooper, W. O. et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N. Engl. J. Med. 354, 2443–2451 (2006).
Framarino-dei-Malatesta, M. et al. Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature. Expert. Rev. Clin. Immunol. 9, 781–789 (2013).
Tangren, J. et al. Pre-pregnancy eGFR and the risk of adverse maternal and fetal outcomes: a population-based study. J. Am. Soc. Nephrol. 34, 656–667 (2023).
Dao, K. H. & Bermas, B. L. Systemic lupus erythematosus management in pregnancy. Int. J. Womens Health 14, 199–211 (2022).
Gotestam Skorpen, C. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann. Rheum. Dis. 75, 795–810 (2016).
Naderi, S. H., Bestwick, J. P. & Wald, D. S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am. J. Med. 125, 882–887 (2012).
McDonald, H. P., Garg, A. X. & Haynes, R. B. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288, 2868–2879 (2002).
Sontakke, S., Budania, R., Bajait, C., Jaiswal, K. & Pimpalkhute, S. Evaluation of adherence to therapy in patients of chronic kidney disease. Indian. J. Pharmacol. 47, 668–671 (2015).
Tuot, D. S. et al. Usability testing of the kidney score platform to enhance communication about kidney disease in primary care settings: qualitative think-aloud study. JMIR Form. Res. 6, e40001 (2022).
Justad, H., Askfors, Y., Shemeikka, T., Andersson, M. L. & Hammar, T. Patients’ use and perceptions of a drug-drug interaction database: a survey of Janusmed interactions. Pharmacy 9, 23 (2021).
Bowman, C. et al. A patient safety educational tool for patients with chronic kidney disease: development and usability study. JMIR Form. Res. 4, e16137 (2020).
Michel, G., Levy, B., Chauvet, M. T., Chauvet, J. & Acher, R. Non-mammalian “big” neurophysins-complete amino acid sequence of a two-domain MSEL-neurophysin from goose. Int. J. Pept. Protein Res. 36, 302–307 (1990).
Lopez-Vargas, P. A., Tong, A., Howell, M. & Craig, J. C. Educational interventions for patients with CKD: a systematic review. Am. J. Kidney Dis. 68, 353–370 (2016).
Watson, K. E. et al. Sick day medication guidance for people with diabetes, kidney disease, or cardiovascular disease: a systematic scoping review. Kidney Med. 4, 100491 (2022).
Duong, H. et al. Sick day management in people with chronic kidney disease: a scoping review. J. Nephrol. 36, 1293–1306 (2023).
Watson, K. E. et al. Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified Delphi process. Am. J. Kidney Dis. 81, 564–574 (2023).
Fink, J. C. et al. Medication holds in CKD during acute volume-depleting illnesses: a randomized controlled trial of a “Sick-Day” protocol. Kidney Med. 4, 100527 (2022).
Humphrey, T. J. L., James, G., Wittbrodt, E. T., Zarzuela, D. & Hiemstra, T. F. Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD). Clin. Kidney J. 14, 2203–2212 (2021).
Morris, R. L. et al. Preventing acute kidney injury: a qualitative study exploring ‘sick day rules’ implementation in primary care. BMC Fam. Pract. 17, 91 (2016).
Martindale, A. M. et al. Understanding the implementation of ‘sick day guidance’ to prevent acute kidney injury across a primary care setting in England: a qualitative evaluation. BMJ Open. 7, e017241 (2017).
Al Raiisi, F. et al. Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review. Int. J. Clin. Pharm. 41, 630–666 (2019).
Joy, M. S. et al. Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy. Am. J. Kidney Dis. 45, 1105–1118 (2005).
Sonoda, A. et al. In-hospital prescription checking system for hospitalized patients with decreased glomerular filtration rate. Kidney360 3, 1730–1737 (2022).
Bhardwaja, B. et al. Improving prescribing safety in patients with renal insufficiency in the ambulatory setting: the Drug Renal Alert Pharmacy (DRAP) program. Pharmacotherapy 31, 346–356 (2011).
Awdishu, L. et al. The impact of real-time alerting on appropriate prescribing in kidney disease: a cluster randomized controlled trial. J. Am. Med. Inf. Assoc. 23, 609–616 (2016).
Erler, A. et al. How to improve drug dosing for patients with renal impairment in primary care — a cluster-randomized controlled trial. BMC Fam. Pract. 13, 91 (2012).
Such Diaz, A. et al. Drug prescribing in patients with renal impairment optimized by a computer-based, semi-automated system. Int. J. Clin. Pharm. 35, 1170–1177 (2013).
Fussell, S. E. et al. Improving the accuracy of discharge medication documentation in people with kidney disease through pharmacist-led partnered prescribing. Intern. Med. J. 53, 2102–2110 (2023).
Chertow, G. M. et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 286, 2839–2844 (2001).
Goldstein, S. L. et al. A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children. Kidney Int. 97, 580–588 (2020).
Kashani, K. B. et al. Digital health and acute kidney injury: consensus report of the 27th Acute Disease Quality Initiative workgroup. Nat. Rev. Nephrol. 19, 807–818 (2023).
Bodington, R., Kassianides, X. & Bhandari, S. Point-of-care testing technologies for the home in chronic kidney disease: a narrative review. Clin. Kidney J. 14, 2316–2331 (2021).
Vanholder, R. et al. Inequities in kidney health and kidney care. Nat. Rev. Nephrol. 19, 694–708 (2023).
Francis, A. et al. Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries|. Kidney Int. 102, 969–973 (2022).
Giorgino, F., Vora, J., Fenici, P. & Solini, A. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovasc. Diabetol. 19, 196 (2020).
Neuen, B. L. et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 7, 845–854 (2019).
Vitale, M., Haxhi, J., Cirrito, T. & Pugliese, G. Renal protection with glucagon-like peptide-1 receptor agonists. Curr. Opin. Pharmacol. 54, 91–101 (2020).
The EMPA-KIDNEY Collaborative Group et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117–127 (2022).
Taglione, M. S. & Persaud, N. Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study. BMJ Open. 11, e045262 (2021).
Jha, V. & Adu, D. Change and choice: research and evidence-informed policy. Nat. Rev. Nephrol. 17, 9–10 (2021).
Nee, R., Yuan, C. M., Narva, A. S., Yan, G. & Norris, K. C. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol. Dial. Transpl. 38, 532–541 (2023).
- The Renal Warrior Project. Join Now
- Source: https://www.nature.com/articles/s41581-024-00823-3